Conversion of Nightingale Health Plc’s Series A shares to Series B shares
Nightingale Health Plc
Company release
11 June 2024 at 2:50 p.m. (EEST)
The Board of Directors of Nightingale Health Plc (“Nightingale Health”) has in its meeting on 20 May 2024, approved request of shareholders to convert 806,680 Series A shares to Series B shares in accordance with Article 5 in the Articles of Association.
As a result of conversion of shares, the number of the Nightingale Health’s Series A shares is 19,779,244, Series B shares is 40,040,415 and EMP shares is 1,098,800. The conversion does not affect the total amount of shares which is 60,918,459. The number of votes of Nightingale Health’s shares is after the conversion 237,832,855.
The conversions of shares were registered in the Trade Register on 11 June 2024. The converted shares will be listed on the Nasdaq Helsinki Ltd together with the old shares as of 12 June 2024.
For further information, please contact:
Teemu Suna, CEO
Certified Adviser:
Oaklins Merasco Ltd. tel. +358 9 6129 670
About Nightingale Health
Nightingale Health’s mission is to build sustainable healthcare and reduce health inequalities. Nightingale Health has developed the world’s most advanced health check that provides risk detection for multiple chronic diseases from a single blood sample. Nightingale’s Health Check can be scaled to entire populations at a low cost, and it can replace many of the current clinical risk assessments. Detecting disease risks on a population level allows for the effective targeting and tracking of health interventions, and better prevention of the onset of chronic diseases. With every sample we help to create a healthier world.
Nightingale Health operates globally with a parent company in Finland and seven subsidiaries in countries such as Japan, the United States, Singapore, and the United Kingdom. Nightingale Health has customers in more than 34 countries in the healthcare and medical research sectors. The company’s technology is being used in many of the world’s leading health initiatives, such as the UK Biobank, and over 600 peer-reviewed publications validate the technology. The company’s Series B shares are listed on the First North Growth Market Finland marketplace. Read more: https://nightingalehealth.com
